Li Yuan, PE, LEED AP, Vice President
Director, Pharmaceutical Business Unit,
Century 3, and Keith McElkearney, Key
Account Manager, BioPharma, Lotus Works,
participated in the round table. Their
edited responses from the Q&A session are
Q. How would you describe the
pharmaceutical climate in your
Yuan [China]: The state of
pharmaceutical climate in China is moving
in a very positive direction due to the
many recent changes within the healthcare
system. In recent years, China’s central
government has been working hard to make
healthcare affordable for everyone.
The general idea is something similar
to Obamacare in the U.S. As a result,
the government is encouraging more
investment in R&D and we have
experienced an increase in job creation.
There is no question that the sheer size
of the Chinese market and the number of
potential patients who will soon be more
participatory in the healthcare system is a
big driver for pharmaceutical companies,
both international and local.
We are definitely seeing an increase in the
number of biotech companies and the sense
of urgency for international companies
to keep up with that local competition
is increasing. Over the past (few) years,
companies such as Pfizer and AstraZeneca
have done major projects here in China.
Our clients in pharma and biotech are very
interested in new ideas and technology.
Some of the cutting edge technology is
very expensive; however, clients are still
interested in how it works and seeing if it is
worth an investment down the road.
McElkearney [Ireland]: Challenging.
Most of the competition in this sector
are from a client’s sister sites. The most
efficient, competent sites are seeing the
work migrate to their site as part of a global
corporate decision. Therefore, each site
wants innovation, pace, reliability so they
can compete with each other.
Q. How much of your country’s
pharmaceutical climate is impacted
by global operations?
Yuan [China]: China is being positively
affected from Western influences and
global operations. Over the past few years
we have seen an increase in the amount
of international pharmaceutical companies
who choose to do business in China.
And on the technology front, the
government has been highly encouraging
of biotech start-ups; Chinese residents
may go oversees for education and then
come back to China and start their own
business in biotech areas, which the Chinese
government encourages and supports.
McElkearney [Ireland]: We are
seeing large investment in Ireland on the
production sites due to the capability and
capacity for growth on existing sites. The
products are sold on a global market,
so issues like the number of countries
distributing the product as well as
established products reaching the end of the
patent can have an impact on the client and
therefore on to us.
Q. What are some of the upcoming
innovations that are changing
the way that the pharmaceutical/
Yuan [China]: Many of the innovations
in the pharma and biopharma industry are
becoming very globalized. For example, all
major companies are providing single-use